In the BioHarmony Drug Report Database
Ozanimod
Zeposia (ozanimod) is a small molecule pharmaceutical. Ozanimod was first approved as Zeposia on 2020-03-25. It is used to treat relapsing-remitting multiple sclerosis in the USA. It has been approved in Europe to treat relapsing-remitting multiple sclerosis. The pharmaceutical is active against sphingosine 1-phosphate receptor 1 and sphingosine 1-phosphate receptor 5. In addition, it is known to target sphingosine 1-phosphate receptor 2, sphingosine 1-phosphate receptor 4, and sphingosine 1-phosphate receptor 3. Zeposia’s patents are valid until 2030-11-15 (FDA).
Trade Name
|
Zeposia |
|---|---|
Common Name
|
ozanimod |
ChEMBL ID
|
CHEMBL3707247 |
Indication
|
relapsing-remitting multiple sclerosis |
Drug Class
|
Immunomodulators |
Image (chem structure or protein)